## **STS/EACTS Latin America Cardiovascular Surgery Conference** September 21-22, 2017 | Cartagena, Colombia

info@cardiovascularsurgeryconference.org www.CardiovascularSurgeryConference.org Myocardial Hybrid Revascularization vs. Coronary Artery Bypass Grafting for Complex Triple-Vessel Disease— Preliminary Results of the Merging Randomized Clinical Trial: Pilot Phase

Dr. Marco Antonio Praca Oliveira Cardiovascular Surgery Heart Institute (InCor) São Paulo University – School of Medicine



The Society of Thoracic Surgeons










# NO DISCLOSURE

### Initial Experience with Minimally Invasive CABG (Partial Sternotomy Off-Pump LITA – LAD)







Ann Thorac Surg. 2002;73(2):505-10. Heart Surg Forum. 2002;5 Suppl 4:S362-77



#### Minimally Invasive Single-vessel Coronary Artery Bypass (LITA – LAD)






Ann Thorac Surg. 2002;73(2):505-10. Heart Surg Forum. 2002;5 Suppl 4:S362-77




## **A Doctor's Vision of the Future of Medicine**

- It like to call it 4P medicine:
- predictive
- preventive
- personalized
- participatory

#### Jun 26, 2009 8:00 PM EDT






Diabetes

Elderly / frail

## "Identify vulnerable groups and join efforts to optimize all assistance"

Comorbidities



Female

### ClinicalTrials.gov

#### **MERGING Clinical Trial**

Myocardial hybrid revascularization versus coronary artERy bypass GraftING for complex triple-vessel disease

- ClinicalTrials.gov Identifier: NCT02226900
  - Sponsor: InCor Heart Institute
- Collaborator: Boston Scientific Corporation
- Responsible Party: Pedro A. Lemos, Luiz A Lisboa

## **Hybrid Revascularization**

"Gold Standard" LITA - LAD

Rationale Hybrid Revascularization


#### **Off-Pump CABG**


**Stent - DES** 

← → C   Seguro   https://red	dcaj	p.ho	c.fm.usp.br/	redcap_	v6.16.4/DataEn	try/record	d_sta
REDCap		1	The MEF	RGING	Clinical Tri	al	
Including Constraints Issue of the second secon			Displayed be data collectio colored butto record on tha	low is a ta n instrume ns in the ta t particula	s Dashboard ble listing all existi ent (and if longitud able to open a new r data collection in ricted for certain d	ing records inal, for ev v tab/windo istrument. I	/resp ery e ow in Pleas
Data Collection	Ξ	1	to view those	instrumer	nts, and if you belo at belong to your o	ong to a Da	
Record Status Dashboard Add / Edit Records	_		Displaying	-	"1401-H" through		• 0
	Ξ		Displaving:	Instrume	nt status only   L	ock status (	only
Calendar Data Exports, Reports, and Stats Data Import Tool Data Comparison Tool Logging			Study ID	Selection Patient		Baseline Data Baseline Data	Ran Rar
🛜 Field Comment Log		,	<u>1401-H</u>		•		
File Repository User Rights and A DAGs			<u>1402-C</u>				
Data Quality		,	<u>1403-H</u> <u>1404-H</u>				
Reports // Edit reports		,	<u>1405-C</u>			$\overline{\bullet}$	
1) Fernanda PCI		,	<u>1406-H</u>			Õ	
<ul><li>2) Demographics</li><li>3) Baseline Data</li></ul>			<u>1407-H</u>	۲	۲	۲	
4) Randomization			<u>1408-H</u>	۲	۲	۲	
5) Surgery 6) PCI			<u>1409-C</u>	۲	۲	۲	
7) ICU 8) Discharge			<u>1410-H</u>	۲	۲	۲	
9) Follow up 30			<u>1411-C</u>	۲	۲	۲	
<ul><li>10) Follow up 180</li><li>11) Follow up 1a</li><li>12) Follow up 2a</li></ul>		,	<u>1412-H</u>	۲	۲	۲	
		,	<u>1513-H</u>	۲	۲	۲	
(i) Help & Information		,	<u>1514-C</u>	۲	۲	۲	
0			<u>1515-H</u>				
<ul> <li>Help &amp; FAQ</li> <li>Video Tutorials</li> </ul>			<u>1516-H</u>				
Suggest a New Feature		,	<u>1517-H</u>				
			<u>1518-C</u>			۲	

#### ls)


ponses and their status for every event). You may click any of the n your browser to view that ase note that if your form-level nstruments, you will only be able Access Group, you will only be






#### | All status types

Randomization Form Randomization	Surgery Surgery	PCI PCI	ICU ICU	Discharge Discharge	Fellow up Follow- up 30	Fellow up Follow- up 180	Fellow up Follow- up 1a	Fellow up Follow- up 2a	Fellow up Follow- up 3a	Fellow up Follow- up 5a	Completion Data Completetion Date
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲		۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲		۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲	$\bigcirc$	$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲		۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲		۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	$\bigcirc$	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲		$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲	$\bigcirc$	$\bigcirc$	
۲	۲	۲	۲	۲	۲	۲	۲	۲	$\bigcirc$	$\bigcirc$	
۲	۲		۲	۲	۲	۲	۲	۲	$\bigcirc$	$\bigcirc$	
	-	$\sim$	$\sim$	~		-	-	-	-	-	



## LITA - LAD



Devecementia dete	Hybrid Revascularization	CABG	Р	
Demographic date	n=31	n=15		
Male sex	25 (80.6%)	13 (86.7%)	1,000	
Age (year)	60.58 ± 8.14	60.4 ± 9.25	0,946	
Body-mass index	27.49 ± 3.12	$28.00 \pm 3.96$	0,637	
Clearence creatinine	82.32 ± 22.64	83.84 ± 27.47	0,843	
Diabetes melittus	11 (35.5%)	8 (53.3%)	0,249	
Glycated haemoglobin	6.15 (5.80 - 6.98)	6.2 (5.68 - 8.6)	0,739	
Insulin-dependent diabetes mellitus	2 (18.2%)	2 (25.0%)	1,000	
Prior myocardial infarction	14 (45.2%)	3 (20.0%)	0,097	
Left ventricular ejection fraction	60 (55 - 65)	63 (58 - 69)	0,153	
Diagnostic at the time of the procedure			0,663	
Chronic coronary artery disease	27 (90.0%)	14 (93.3%)		
Instable angina	1 (3.3%)	0 (0%)		
Acute myocardial infarction	2 (6.7%)	1 (6.7%)		
Extent of coronary artery disease				
Three-vessel disease	31 (100%)	15 (100%)	1,000	
Left main coronary artery disease	2 (6.5%)	1 (6.7%)	1,000	

Diale Caara	Hybrid Revascularization	CABG	D
Risk Score	n=31	n=15	P
	0.93 (0.67 - 1.28)	0.98 (0.87 - 1.24)	0,392
STS risk of mortality	0.5 (0.35 - 0.93)	0.65 (0.42 - 0.84)	0,489
STS risk of morbidity or mortality	7.42 (6.24 - 9.96)	8.85 (6.59 - 11.31)	0,682
Syntax score	26.5 (24.0 - 32.0)	29.0 (26.0 - 32.0)	0,317
PCI Syntax score II	30.40 (25.10 - 35.75)	32.40 (26.50 - 36.25)	0,446
PCI Mortality Syntax score II	7.0 (4.6 - 10.8)	8.3 (5.2 - 11.3)	0,471
CABG Syntax score II	23.2 (14.95 - 33.9)	28.4 (13.4 - 33.8)	0,860
CABG Mortality Syntax score II	3.9 (2.0 - 9.3)	6.0 (1.7 - 9.3)	0,838
Treatment recommendation			0,564
CABG or PCI	20 (69%)	8 (61.5%)	
CABG	8 (27.6%)	5 (38.5%)	
PCI	1 (3.4%)	0 (0%)	

Oporativo variables	Hybrid Revascularization	CABG	Р	
Operative variables	n=31	n=15	F	
No of vessels grafted			<0.001	
1	31 (100%)	0 (0%)		
2	0 (0%)	2 (13.3%)		
3	0 (0%)	<b>)</b> 11 (73.3%)		
4	0 (0%)	2 (13.3%)		
On-Pump CABG	0 (0%)	15 (100%)	<0.001	
Anesthesia time	03:30 (03:15 - 03:50)	06:00 (05:20 - 06:00)	<0.001	
Surgery time	02:00 (01:50 - 02:20)	04:20 (04:00 - 04:45)	<0.001	
Blood transfusion	2 (6.5%)	2 (13.3%)	0,587	
Number of vessels treated with stents				
1	3 (10.3%)			
2	11 (37.9%)			
3	13 (44.8%)			
4	2 (6.9%)			
Planned procedure performed	29 (93.5%)	15 (100%)	1,000	
Freatment crossover	1 (3.2%)	0 (0%)	1,000	

Intra-hospitalar pos-operative	Hybr
MACCE	
Myocardial Infarction	
Repeat revascularization	
Stroke	
Death	

Hybrid Revascularization	CABG	Р
n=32	n=15	
3 (9.7%)	0 (0%)	0,541
2 (6.5%)	0 (0%)	1,000
0 (0%)	0 (0%)	1,000
0 (0%)	0 (0%)	1,000
1 (3.2%)	0 (0%)	1,000

Follow-up at 1 year	Hybrid Revascularization	CABG	Ρ
	n=31	n=15	F
MACCE	0 (0%)	1 (7.7%)	0,351
Myocardial Infarction	0 (0%)	1 (7.7%)	0,351
Repeat revascularization	0 (0%)	1 (7.7%)	0,351
Stroke	0 (0%)	0 (0%)	1,000
Death	0 (0%)	0 (0%)	1,000

revascularization is proceeding slowly based on individuals experiential.

To date, there has been no multicenter randomized controlled trial to establish whether hybrid revascularization achieves effort to reduce morbidity and mortality for patients with multi-vessel coronary artery disease, and increasing adoption of hybrid

- revascularization by the hybrid techinic was not statistically different than the control group regarding the incidence of major adverse cardiovascular events. All the patients with primary in hospital outcome were allocated in the hybrid group and events occurred between de two stages of procedure, that is, prior to PCI. By one year there were no events in the hybrid group.
- The preliminary analysis of the study demonstrated that the strategy of  $\bullet$
- The low sample number does not provid precision for the analysis, and there is a need for multicenter studies.

### CONCLUSION

## **STS/EACTS Latin America Cardiovascular Surgery Conference** September 21-22, 2017 | Cartagena, Colombia

info@cardiovascularsurgeryconference.org www.CardiovascularSurgeryConference.org

## Thank You doutormarquito@gmail.com



The Society of Thoracic Surgeons





